Annual FCF
$13.17 M
+$7.47 M+130.99%
December 31, 2023
Summary
- As of February 8, 2025, KNSA annual free cash flow is $13.17 million, with the most recent change of +$7.47 million (+130.99%) on December 31, 2023.
- During the last 3 years, KNSA annual FCF has risen by +$149.99 million (+109.63%).
- KNSA annual FCF is now at all-time high.
Performance
KNSA Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$2.24 M
-$7.40 M-143.27%
September 30, 2024
Summary
- As of February 8, 2025, KNSA quarterly free cash flow is -$2.24 million, with the most recent change of -$7.40 million (-143.27%) on September 30, 2024.
- Over the past year, KNSA quarterly FCF has dropped by -$19.21 million (-113.18%).
- KNSA quarterly FCF is now -103.60% below its all-time high of $62.03 million, reached on September 30, 2022.
Performance
KNSA Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
$11.10 M
-$19.21 M-63.37%
September 30, 2024
Summary
- As of February 8, 2025, KNSA TTM free cash flow is $11.10 million, with the most recent change of -$19.21 million (-63.37%) on September 30, 2024.
- Over the past year, KNSA TTM FCF has increased by +$13.75 million (+520.29%).
- KNSA TTM FCF is now -73.82% below its all-time high of $42.42 million, reached on June 30, 2023.
Performance
KNSA TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
KNSA Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +131.0% | -113.2% | +520.3% |
| 3 y3 years | +109.6% | +92.2% | +106.6% |
| 5 y5 years | +115.3% | +92.5% | +106.9% |
KNSA Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +109.0% | -103.6% | +93.9% | -73.8% | +107.6% |
| 5 y | 5-year | at high | +108.2% | -103.6% | +96.3% | -73.8% | +106.4% |
| alltime | all time | at high | +108.2% | -103.6% | +96.5% | -73.8% | +106.4% |
Kiniksa Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$2.24 M(-143.3%) | $11.10 M(-63.4%) |
| Jun 2024 | - | $5.17 M(+32.4%) | $30.31 M(+41.9%) |
| Mar 2024 | - | $3.90 M(-8.6%) | $21.36 M(+62.2%) |
| Dec 2023 | $13.17 M(+131.0%) | $4.27 M(-74.8%) | $13.17 M(-598.5%) |
| Sep 2023 | - | $16.97 M(-549.3%) | -$2.64 M(-106.2%) |
| Jun 2023 | - | -$3.78 M(-12.0%) | $42.42 M(+10.9%) |
| Mar 2023 | - | -$4.29 M(-62.8%) | $38.26 M(+570.9%) |
| Dec 2022 | $5.70 M(-103.9%) | -$11.54 M(-118.6%) | $5.70 M(-401.9%) |
| Sep 2022 | - | $62.03 M(-881.3%) | -$1.89 M(-98.0%) |
| Jun 2022 | - | -$7.94 M(-78.5%) | -$92.48 M(-25.0%) |
| Mar 2022 | - | -$36.85 M(+92.6%) | -$123.38 M(-15.9%) |
| Dec 2021 | -$146.71 M(+7.2%) | -$19.14 M(-33.0%) | -$146.71 M(-13.1%) |
| Sep 2021 | - | -$28.56 M(-26.5%) | -$168.82 M(-3.3%) |
| Jun 2021 | - | -$38.84 M(-35.5%) | -$174.59 M(+5.8%) |
| Mar 2021 | - | -$60.18 M(+45.9%) | -$164.97 M(+20.6%) |
| Dec 2020 | -$136.81 M | -$41.25 M(+20.2%) | -$136.81 M(+12.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$34.33 M(+17.5%) | -$121.73 M(+3.9%) |
| Jun 2020 | - | -$29.22 M(-8.7%) | -$117.12 M(-9.1%) |
| Mar 2020 | - | -$32.02 M(+22.4%) | -$128.77 M(-20.3%) |
| Dec 2019 | -$161.57 M(+87.2%) | -$26.17 M(-11.9%) | -$161.57 M(-3.3%) |
| Sep 2019 | - | -$29.71 M(-27.3%) | -$167.06 M(+5.2%) |
| Jun 2019 | - | -$40.88 M(-36.9%) | -$158.80 M(+16.7%) |
| Mar 2019 | - | -$64.82 M(+104.8%) | -$136.07 M(+57.7%) |
| Dec 2018 | -$86.30 M(+71.6%) | -$31.65 M(+47.6%) | -$86.30 M(+10.6%) |
| Sep 2018 | - | -$21.45 M(+18.2%) | -$78.03 M(+15.5%) |
| Jun 2018 | - | -$18.15 M(+20.6%) | -$67.55 M(+13.3%) |
| Mar 2018 | - | -$15.05 M(-35.6%) | -$59.64 M(+18.6%) |
| Dec 2017 | -$50.29 M(+129.9%) | -$23.38 M(+113.1%) | -$50.29 M(+86.9%) |
| Sep 2017 | - | -$10.97 M(+7.2%) | -$26.91 M(+68.9%) |
| Jun 2017 | - | -$10.24 M(+79.7%) | -$15.93 M(+179.7%) |
| Mar 2017 | - | -$5.70 M | -$5.70 M |
| Dec 2016 | -$21.87 M | - | - |
FAQ
- What is Kiniksa Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Kiniksa Pharmaceuticals?
- What is Kiniksa Pharmaceuticals annual FCF year-on-year change?
- What is Kiniksa Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Kiniksa Pharmaceuticals?
- What is Kiniksa Pharmaceuticals quarterly FCF year-on-year change?
- What is Kiniksa Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Kiniksa Pharmaceuticals?
- What is Kiniksa Pharmaceuticals TTM FCF year-on-year change?
What is Kiniksa Pharmaceuticals annual free cash flow?
The current annual FCF of KNSA is $13.17 M
What is the all time high annual FCF for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals all-time high annual free cash flow is $13.17 M
What is Kiniksa Pharmaceuticals annual FCF year-on-year change?
Over the past year, KNSA annual free cash flow has changed by +$7.47 M (+130.99%)
What is Kiniksa Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of KNSA is -$2.24 M
What is the all time high quarterly FCF for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals all-time high quarterly free cash flow is $62.03 M
What is Kiniksa Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, KNSA quarterly free cash flow has changed by -$19.21 M (-113.18%)
What is Kiniksa Pharmaceuticals TTM free cash flow?
The current TTM FCF of KNSA is $11.10 M
What is the all time high TTM FCF for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals all-time high TTM free cash flow is $42.42 M
What is Kiniksa Pharmaceuticals TTM FCF year-on-year change?
Over the past year, KNSA TTM free cash flow has changed by +$13.75 M (+520.29%)